RecruitingPhase 3NCT05432466

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

Studying Vascular Ehlers-Danlos syndrome

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Acer Therapeutics Inc.
Principal Investigator: Sheila Woodhouse, MD; Ph.D.
Intervention: ACER-002 (celiprolol) 200 mg BID(drug)
Enrollment: 150 enrolled
Eligibility: 15-64 years · All sexes
Timeline: 2022 – 2029

Study locations (1)

Science 37, Culver City, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05432466 on ClinicalTrials.gov

Other trials for Vascular Ehlers-Danlos syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT05994664
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Baylor College of Medicine

See all trials for Vascular Ehlers-Danlos syndrome →

← Back to all trials